Guess which ASX 300 stock is jumping amid huge profit growth

The company is forecasting its profits to more than double in the first half.

| More on:
A young woman with her mouth open and her hands out showing surprise and delight as uranium share prices skyrocket

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Nanosonics Ltd (ASX: NAN) shares are having a strong session on Thursday.

In early trade, the ASX 300 stock is up 6% to $3.97.

Why is this ASX 300 stock is jumping?

Investors have been buying the infection prevention company's shares this morning following the release of a half-year update.

According to the release, Nanosonics is expecting to report a sizeable increase in revenue and profits for the half after returning to form in FY 2025.

For the six months ended 31 December, the ASX 300 stock expects total revenue to be approximately $93.6 million. This is up 18% from $79.6 million in the prior corresponding period. It is also up 4% from the $90.4 million recorded in the second half of FY 2024.

Commenting on its top line performance during the half, the company's CEO and president, Michael Kavanagh, said:

The expected first half revenue result of $93.6m represents a good start to the year up 18% compared to pcp and 4% compared to H2 FY24. Revenue growth was primarily driven by 20% growth (compared to pcp) in our consumables and service annuity revenue streams. The total number of trophon units sold in the first half was broadly in line with internal forecasts and was similar to the total number sold in the pcp, with overall capital revenue up 11% compared to pcp.

Strong profit growth

The company's gross margin for the half is expected to be approximately 78.5%. This is down from 79.7% in the prior corresponding period but up from 76.3% in the second half of FY 2024.

Nanosonics' operating expenses are expected to be approximately $66.7 million for the half. This is up 10% from the prior corresponding period and 3% on the previous half.

Nevertheless, this couldn't stop the ASX 300 stock from delivering strong profit growth. Management expects a profit before tax of approximately $10.9 million for the six months. This is more than double the $4.9 million recorded in the prior corresponding period and is up from $8.1 million in second half of FY 2024.

CEO Michael Kavanagh revealed that some of this profit growth comes from one-offs. He explains:

As a result of the increased first half revenue, the business expects to deliver profit before tax (PBT) of $10.9 million for the half. The expected PBT result includes a gain of approximately $1.3 million (compared to a $0.4 million loss in H1 FY24) due to the AUD exchange rate moving from 0.66 on 30 June 2024 to 0.62 on 31 December 2024. This movement created an unrealised FX gain on US dollar-denominated assets, partially offset by the group's hedging activities.

Outlook

Kavanagh believes that Nanosonics' first half performance means that it is on track to "achieve revenue, gross margin and operating expenses in FY25 around the top of each of the ranges for those measures specified in Nanosonics' FY25 outlook statement."

This includes total revenue growth of 8% to 12%, a gross margin of 77% to 79%, and operating expense growth of 6% to 10%.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Nanosonics. The Motley Fool Australia has positions in and has recommended Nanosonics. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man looking at his laptop and thinking.
Earnings Results

CSL shares push higher despite 'mixed result with headline misses'

There were positives and negatives in the company's first half performance.

Read more »

Scientists working in the laboratory and examining results.
Earnings Results

CSL share price on watch amid $2.1b half year profit and dividend hike

Let's see how this biotech giant performed during the first half of FY 2025.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 300 healthcare stock just rocketed 20% on BIG earnings growth

Investors are piling into the ASX 300 healthcare stock on Monday. But why?

Read more »

Health professional putting on gloves.
Earnings Results

Why this ASX 200 share is soaring in Monday's sinking market

The ASX 200 share is shrugging off the broader market fall today to rocket higher. But why?

Read more »

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

Why is the Sigma share price soaring 6%?

Sigma has upgraded its FY25 guidance ahead of the anticipated Chemist Warehouse merger completion.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Which ASX 200 healthcare share will pay the best dividend yield in 2025?

Earnings season is underway and dividend announcements are on investors' minds.

Read more »

A person is weighed down by a huge stack of coins, they have received a big dividend payout.
Dividend Investing

Looking to bag the record high ResMed dividend? You better hurry!

Unlike the majority of ASX 200 income stocks, ResMed pays dividends every quarter.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

3 reasons to buy CSL shares today

Two investment experts expect a big turnaround for CSL shares in 2025.

Read more »